Ad
ATRS - Antares Pharma Stock Trading
About | Antares Pharma Inc. (NASDAQ:ATRS)
Not available
Quote | Antares Pharma Inc. (NASDAQ:ATRS)
| Last: | $5.59 |
|---|---|
| Change Percent: | 0.0% |
| Open: | $0 |
| Close: | $5.59 |
| High: | $0 |
| Low: | $0 |
| Volume: | 3,890 |
| Last Trade Date Time: | 12/31/1969 07:00:00 pm |
News | Antares Pharma Inc. (NASDAQ:ATRS)
-
Halozyme Therapeutics announced that they are acquiring Antares Pharma at $5.60 per share in cash, for a total of ~$960M. The deal is expected to close in 1H of 2022. Antares develops products utilizing their drug delivery systems and has multiple royalty streams for their auto-inject...
-
Form 13F filings show fund managers' top merger arbitrage stocks. Top M&A stocks of the 31 funds I follow. Cerner the top merger arb stock. For further details see: Top Merger Stocks Held By Fund Managers, Mid-Q2 2022
Message Board Posts | Antares Pharma Inc. (NASDAQ:ATRS)
| Subject | By | Source | When |
|---|---|---|---|
| Ok boys time to cash out. Antares | La Chef | investorshub | 05/03/2022 3:24:56 PM |
| whytestocks: $ATRS News Article - Advancements of CAR-T Cell Therapies Importance Grows While Cancer | whytestocks | investorshangout | 04/14/2022 12:45:52 PM |
| whytestocks: $ATRS News Article - ANTARES PHARMA ALERT: Bragar Eagel & Squire, P.C. Investigates Mer | whytestocks | investorshangout | 04/13/2022 6:05:51 PM |
| whytestocks: $ATRS News Article - Antares Pharma Inc shares up 45% on Wednesday: how come? | whytestocks | investorshangout | 04/13/2022 5:45:52 PM |
| whytestocks: $ATRS News Article - Lifshitz Law PLLC Announces Investigation of ATRS, HBP, OBNK, ZWS | whytestocks | investorshangout | 04/13/2022 2:45:51 PM |
News, Short Squeeze, Breakout and More Instantly...
Ad
-
Hart-Scott-Rodino Waiting Period Expires for Halozyme's Acquisition of Antares Pharma PR Newswire SAN DIEGO , May 12, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (" Halozyme ") today announced that the waiting period unde...
-
Antares Pharma Inc shares ( NASDAQ: ATRS ) are up 45% on Wednesday after Halozyme Therapeutics said it will buy the New Jersey-headquartered company for $960 million in cash. Details of the agreement The deal translates to $5.60 per share for Antares Pharma shareholders that...